---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-253174"
form_type: "8-K"
ticker: "ACLX"
cik: "0001786205"
company_name: "Arcellx, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:43:27.270119+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Arcellx Q3 net loss narrows; anito-cel hits 95% ORR in pivotal study with no neurotoxicity

## Summary
- Q3 net loss $25.9M ($39.3M YoY); collaboration revenue $26M from Kite expansion.
- Phase 2 iMMagine-1 (n=58): 95% ORR, 62% CR/sCR, median follow-up 10.3 months; 92% MRD negativity.
- Phase 1 anito-cel: 30.2-month mPFS, median OS not reached at 38.1 months; 100% ORR.
- No delayed neurotoxicity (parkinsonism, cranial nerve palsies) in >140 patients across trials.
- Cash $676.7M funds into 2027; first patients dosed in iMMagine-3 with Kite manufacturing.

## SEC filing metadata
- accession: 0001193125-24-253174
- form_type: 8-K
- ticker: ACLX
- cik: 0001786205
- company_name: Arcellx, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1786205/000119312524253174/0001193125-24-253174-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1786205/000119312524253174/d862473d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-253174
- JSON: https://secwatch.observer/filing/0001193125-24-253174.json
- Plain text: https://secwatch.observer/filing/0001193125-24-253174.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.